Canakinumab
Modify Date: 2025-08-25 06:18:53
Canakinumab structure
|
Common Name | Canakinumab | ||
|---|---|---|---|---|
| CAS Number | 914613-48-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CanakinumabCanakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin[1][2]. |
| Name | Canakinumab |
|---|
| Description | Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 43.6 pM (human IL-1β), 40.8 pM (marmoset IL-1β)[2] |
| In Vitro | Canakinumab (0-7 nM) dose dependently represses IL-6 production in marmoset peripheral blood mononuclear cells with IC50s of 43.6 and 40.8 pM for human and marmoset IL-1β[2].Canakinumab effectively competes with IL-1RI and IL-1RII for binding to IL-1b[2]. |
| References |
| No Any Chemical & Physical Properties |